Search Results - "Bayani, Nora"

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease by Smith, Rebecca, Liu, Moqing, Liby, Tiera, Bayani, Nora, Bucher, Elmar, Chiotti, Kami, Derrick, Daniel, Chauchereau, Anne, Heiser, Laura, Alumkal, Joshi, Feiler, Heidi, Carroll, Peter, Korkola, James E.

“…Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving our…”
Get full text

Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells by Chen, Wei-Ching, To, Minh D., Westcott, Peter M. K., Delrosario, Reyno, Kim, Il-Jin, Philips, Mark, Tran, Quan, Bollam, Saumya R., Goodarzi, Hani, Bayani, Nora, Mirzoeva, Olga, Balmain, Allan

“…The commonly mutated human KRAS oncogene encodes two distinct KRAS4A and KRAS4B proteins generated by differential splicing. We demonstrate here that…”
Get full text

Causal network inference using biochemical kinetics by Oates, Chris J, Dondelinger, Frank, Bayani, Nora, Korkola, James, Gray, Joe W, Mukherjee, Sach

“…Networks are widely used as structural summaries of biochemical systems. Statistical estimation of networks is usually based on linear or discrete models…”
Get full text

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes by Neve, Richard M., Chin, Koei, Fridlyand, Jane, Yeh, Jennifer, Baehner, Frederick L., Fevr, Tea, Clark, Laura, Bayani, Nora, Coppe, Jean-Philippe, Tong, Frances, Speed, Terry, Spellman, Paul T., DeVries, Sandy, Lapuk, Anna, Wang, Nick J., Kuo, Wen-Lin, Stilwell, Jackie L., Pinkel, Daniel, Albertson, Donna G., Waldman, Frederic M., McCormick, Frank, Dickson, Robert B., Johnson, Michael D., Lippman, Marc, Ethier, Stephen, Gazdar, Adi, Gray, Joe W.

“…Recent studies suggest that thousands of genes may contribute to breast cancer pathophysiologies when deregulated by genomic or epigenomic events. Here, we…”
Get full text

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition by MIRZOEVA, Olga K, DAS, Debopriya, ZHI HU, KNIGHT, Zachary, FEILER, Heidi S, GASCARD, Philippe, PARVIN, Bahram, SPELLMAN, Paul T, SHOKAT, Kevan M, WYROBEK, Andrew J, BISSELL, Mina J, MCCORMICK, Frank, HEISER, Laura M, KUO, Wen-Lin, MILLS, Gordon B, GRAY, Joe W, KORN, W. Michael, BHATTACHARYA, Sanchita, SIWAK, Doris, GENDELMAN, Rina, BAYANI, Nora, WANG, Nicholas J, NEVE, Richard M, YINGHUI GUAN

“…Specific inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) have been developed that efficiently inhibit…”
Get full text

The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer by Hu, Zhi, Huang, Ge, Sadanandam, Anguraj, Gu, Shenda, Lenburg, Marc E, Pai, Melody, Bayani, Nora, Blakely, Eleanor A, Gray, Joe W, Mao, Jian-Hua

“…HJURP (Holliday Junction Recognition Protein) is a newly discovered gene reported to function at centromeres and to interact with CENPA. However its role in…”
Get full text

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer by Korkola, James E, Collisson, Eric A, Heiser, Laura, Oates, Chris, Bayani, Nora, Itani, Sleiman, Esch, Amanda, Thompson, Wallace, Griffith, Obi L, Wang, Nicholas J, Kuo, Wen-Lin, Cooper, Brian, Billig, Jessica, Ziyad, Safiyyah, Hung, Jenny L, Jakkula, Lakshmi, Feiler, Heidi, Lu, Yiling, Mills, Gordon B, Spellman, Paul T, Tomlin, Claire, Mukherjee, Sach, Gray, Joe W

“…We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We…”
Get full text

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer by Korkola, James E, Collisson, Eric A, Heiser, Laura M, Oates, Chris, Bayani, Nora, Itani, Sleiman, Esch, Amanda, Thompson, Wallace, Griffith, Obi L, Wang, Nicholas J, Kuo, Wen-Lin, Cooper, Brian, Billig, Jessica, Ziyad, Safiyyah, Hung, Jenny L, Jakkula, Lakshmi, Feiler, Heidi, Lu, Yiling, Mills, Gordon B, Spellman, Paul T, Tomlin, Claire, Mukherjee, Sach, Gray, Joe W

“…[This corrects the article DOI: 10.1371/journal.pone.0133219.]…”
Get full text

Integrating biological knowledge into variable selection: an empirical Bayes approach with an application in cancer biology by Hill, Steven M, Neve, Richard M, Bayani, Nora, Kuo, Wen-Lin, Ziyad, Safiyyah, Spellman, Paul T, Gray, Joe W, Mukherjee, Sach

“…An important question in the analysis of biochemical data is that of identifying subsets of molecular variables that may jointly influence a biological…”
Get full text

A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047 by Kuo, Wen-Lin, Das, Debopriya, Ziyad, Safiyyah, Bhattacharya, Sanchita, Gibb, William J, Heiser, Laura M, Sadanandam, Anguraj, Fontenay, Gerald V, Hu, Zhi, Wang, Nicholas J, Bayani, Nora, Feiler, Heidi S, Neve, Richard M, Wyrobek, Andrew J, Spellman, Paul T, Marton, Laurence J, Gray, Joe W

“…Polyamines regulate important cellular functions and polyamine dysregulation frequently occurs in cancer. The objective of this study was to use a systems…”
Get full text

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer by Donnella, Hayley J., Webber, James T., Levin, Rebecca S., Camarda, Roman, Momcilovic, Olga, Bayani, Nora, Shah, Khyati N., Korkola, James E., Shokat, Kevan M., Goga, Andrei, Gordan, John D., Bandyopadhyay, Sourav

“…Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast cancers. However, clinical responses to drugs targeting this pathway have…”
Get full text

Subtype and pathway specific responses to anticancer compounds in breast cancer by Heiser, Laura M, Sadanandam, Anguraj, Kuo, Wen-Lin, Benz, Stephen C, Goldstein, Theodore C, Ng, Sam, Gibb, William J, Wang, Nicholas J, Ziyad, Safiyyah, Tong, Frances, Bayani, Nora, Hu, Zhi, Billig, Jessica I, Dueregger, Andrea, Lewis, Sophia, Jakkula, Lakshmi, Korkola, James E, Durinck, Steffen, Pepin, François, Guan, Yinghui, Purdom, Elizabeth, Neuvial, Pierre, Bengtsson, Henrik, Wood, Kenneth W, Smith, Peter G, Vassilev, Lyubomir T, Hennessy, Bryan T, Greshock, Joel, Bachman, Kurtis E, Hardwicke, Mary Ann, Park, John W, Marton, Laurence J, Wolf, Denise M, Collisson, Eric A, Neve, Richard M, Mills, Gordon B, Speed, Terence P, Feiler, Heidi S, Wooster, Richard F, Haussler, David, Stuart, Joshua M, Gray, Joe W, Spellman, Paul T

“…Breast cancers are comprised of molecularly distinct subtypes that may respond differently to pathway-targeted therapies now under development. Collections of…”
Get full text

Abstract 2387: Activation of Inhibin A signaling is associated with a basal-like HER2 subtype and resistance to lapatinib in breast cancer cell lines by Korkola, James E., Rantala, Juha, Bayani, Nora, Heiser, Laura, Wang, Nicholas, Griffith, Obi, Gray, Joe

“…Abstract HER2 amplification occurs in ∼20% of all breast cancers, and is associated with poor prognosis. Targeted therapeutics such as trastuzumab and…”
Get full text

Abstract 2198: The impact of carcinogens, obesity, and chronic inflammatory processes on mutational signatures and cancer risk in mouse tumor models by Li, Yun Rose, Halliwill, Kyle, Kandyba, Eve, Delrosario, Reyno, Tran, Quan, Bayani, Nora, Wu, Di, Mirzoeva, Olga, Reeves, Melissa McCreery, Islam, Mishu, Riva, Laura, Bergstrom, Eric, Digiovanni, John, Alexandrov, Ludmil, Balmain, Allan

“…Abstract An estimated 40% of all human cancers are suspected to be a result of modifiable risk factors such as obesity, high fat diet and chronic inflammation…”
Get full text

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer by Hu, Zhi, Mao, Jian-Hua, Curtis, Christina, Huang, Ge, Gu, Shenda, Heiser, Laura, Lenburg, Marc E, Korkola, James E, Bayani, Nora, Samarajiwa, Shamith, Seoane, Jose A, Dane, Mark A, Esch, Amanda, Feiler, Heidi S, Wang, Nicholas J, Hardwicke, Mary Ann, Laquerre, Sylvie, Jackson, Jeff, W Wood, Kenneth, Weber, Barbara, Spellman, Paul T, Aparicio, Samuel, Wooster, Richard, Caldas, Carlos, Gray, Joe W

“…High mitotic activity is associated with the genesis and progression of many cancers. Small molecule inhibitors of mitotic apparatus proteins are now being…”
Get full text

Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer by Hu, Zhi, Mao, Jian-Hua, Curtis, Christina, Huang, Ge, Gu, Shenda, Heiser, Laura, Lenburg, Marc E, Korkola, James E, Bayani, Nora, Samarajiwa, Shamith, Seoane, Jose A, Dane, Mark A, Esch, Amanda, Feiler, Heidi S, Wang, Nicholas J, Hardwicke, Mary Ann, Laquerre, Sylvie, Jackson, Jeff, Wood, Kenneth W, Weber, Barbara, Spellman, Paul T, Aparicio, Samuel, Wooster, Richard, Caldas, Carlos, Gray, Joe W

“…In the version of this article that was published on PubMed [1] the author's name "Mark A. Dane" was formatted incorrectly in the XML mark up and therefore…”
Get full text

Abstract 639: Inhibition of HER2 signaling using targeted therapeutics in breast cancer cell lines by Korkola, James, Bayani, Nora, Cooper, Brian, Heiser, Laura M., Spellman, Paul T., Feiler, Heidi S., Wooster, Richard, Gray, Joe W.

“…Abstract ERBB2/HER2 amplification occurs in 20-30% of all breast cancers and is associated with an aggressive clinical behavior. Therapeutics that target HER2…”
Get full text

Abstract 49: Constructing pathway based predictors of cancer clinical outcome by Ng, Sam, Vaske, Charlie, Benz, Steve, Durbin, James, Szeto, Chris, Heiser, Laura, Wang, Nicholas, Korkola, Jim, Bayani, Nora, Spellman, Paul, Gray, Joe W., Haussler, David, Stuart, Joshua

“…Abstract Current efforts to understand the mechanism of cancer involve using various whole-genome -omics measurements over large patient cohorts. Since a…”
Get full text

Abstract A179: Synergistic interactions of Lapatinib and an AKT inhibitor in HER2 positive breast cancer cell lines depends on PI3K pathway status by Korkola, James, Bayani, Nora, Cooper, Brian, Kuo, Wen-Lin, Billig, Jessica, Ziyad, Saffiyah, Feiler, Heidi, Spellman, Paul, Wooster, Richard, Gray, Joe W.

“…Abstract Purpose: Lapatinib is a dual inhibitor of EGFR/HER2. Recent evidence suggests that resistance to HER2 inhibition by lapatinib may be in part due to…”
Get full text

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer: e0133219 by Korkola, James E, Collisson, Eric A, Heiser, Laura, Oates, Chris, Bayani, Nora, Itani, Sleiman, Esch, Amanda, Thompson, Wallace, Griffith, Obi L, Wang, Nicholas J

“…We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2+ breast cancers. We…”
Get full text